Loading market dashboard
GlucoTrack, Inc.
GCTKHealthcareNASDAQIL
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association's (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.
Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform
RUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer reviewed scientific article in The Journal of Diabetes Research on the long-term accuracy and stability of the Company's fully implantable continuous blood glucose monitoring (CBGM) system in an in-vivo ovine model.
RUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal characterizing the long-term in-vitro stability of electrochemical glucose sensors of the type used in the Company's fully implantable continuous blood glucose monitoring (CBGM) system.
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026
GlucoTrack, Inc. (NASDAQ: GCTK - Get Free Report) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 43,428 shares, an increase of 53.5% from the February 26th total of 28,292 shares. Currently, 4.4% of the company's stock are short sold. Based on an average
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026
RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer, will present at LSI USA '26 Summit, taking place March 16-20, 2026, in Dana Point, California.
